NQO1 and acute kidney injury: A preclinical study showed that cotreatment with cisplatin and β-lapachone significantly increased intracellular NAD+ levels and attenuated cisplatin-induced AKI in mice due to the activation of NAD(P)H:quinone oxidoreductase 1 (NQO1) by β-lapachone [165].